The molecular biology of lung cancer brain metastasis: An overview of current comprehensions and future perspectives

Journal of Medical Investigation

Volumn 61, Issue 3-4, 2014, Pages 241-253

  Hanibuchi, Masaki ^a   Kim, Sun Jin ^b   Fidler, Isaiah J ^b   Nishioka, Yasuhiko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brain metastasis; Lung cancer; Molecular biology

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; CRIZOTINIB; ENDOTHELIN; ENDOTHELIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GELATINASE B; INTEGRIN; MICRORNA; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; RHO FACTOR; RHO KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; WNT PROTEIN; CADHERIN; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ASTROCYTE; BLEEDING; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN METASTASIS; CARCINOGENESIS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PENETRATION; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VASCULARIZATION; BRAIN NEOPLASMS; GENETICS; LUNG TUMOR; PATHOLOGY; PHYSIOLOGY; SECONDARY;

ASTROCYTES; BRAIN NEOPLASMS; CADHERINS; HUMANS; INTEGRINS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907512767     PISSN: 13431420     EISSN: 13496867     Source Type: Journal    
DOI: 10.2152/jmi.61.241     Document Type: Review

References (93)

1. Weil R, Palmieri D, Bronder J, Stark A, Steeg PS: Breast cancer metastasis to the central nervous system. Am J Pathol 167: 913-920, 2005
2. Nathoo N, Chahlavi A, Barnett GH, Toms SA: Pathobiology of brain metastases. J Clin Pathol 58: 237-242, 2005
3. Wen PY, Loeffler JS: Brain metastases. Curr Treat Options Oncol 1: 447-458, 2000
4. Kim SH, Chao ST, Toms SA, Vogelbaum MA, Barnett GH, Suh JH, Weil RJ: Sereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma. Surg Neurol 69: 641-646, 2008
5. Soffietti R, Ruda R, Trevisan E: Brain metastases: current management and new developments. Curr Opin Oncol 20: 676-684, 2008
6. Gril B, Evans L, Palmieri D, Steeg PS: Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer 46: 1204-1210, 2010
7. Eichler AF, Loeffler JS: Multidisciplinary management of brain metastases. Oncologist 12: 884-898, 2007
8. Smedby KE, Brandt L, Backlund ML, Blomqvist P: Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 101: 1919-1924, 2009
9. Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR: Immunohistochemical markers associated with brain metastases in patients with non-small cell lung carcinoma. Cancer 113: 2129-2138, 2008
10. Schwer AL, Gaspar LE: Update in the treatment of brain metastases from lung cancer. Clin Lung Cancer 8: 180-186, 2006
11. Paget S: The distribution of secondary growths in cancer of the breast.1889. Cancer Metastasis Rev 8: 98-101, 1989
12. Fidler IJ: The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21: 107-112, 2011
13. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS: The biology of metastasis to a sanctuary site. Clin Cancer Res 13: 1656-1662, 2007
14. Deeken JF, Löscher W: The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13: 1663-1674, 2007
15. Abbott NJ, Ronnback L, Hansson E: Astrocyteendothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: 41-53, 2006
16. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A: Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123: 205-222, 2012
17. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK: The biology of brain meta-stases-translation to new therapies. Nat Rev Clin Oncol 8: 344-356, 2011
18. Kikuchi T, Daigo Y, Ishikawa N, Katagiri T, Tsunoda T, Yoshida S, Nakamura Y: Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 28: 799-805, 2006
19. Zohrabian VM, Nandu H, Gulati N, Khitrov G, Zhao C, Mohan A, Demattia J, Braun A, Das K, Murali R, Jhanwar-Uniyal M: Gene expression profiling of metastatic brain cancer. Oncol Rep 18: 321-328, 2007
20. Grinberg-Rashi H, Ofek E, Perelman M, Skarda J, Yaron P, Hajdúch M, Jacob-Hirsch J, Amariglio N, Krupsky M, Simansky DA, Ram Z, Pfeffer R, Galernter I, Steinberg DM, Ben-Dov I, Rechavi G, Izraeli S: The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 15: 1755-1761, 2009
21. Derycke LD, Bracke ME: N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 48: 463-476, 2004
22. Nakashima T, Huang C, Liu D, Kameyama K, Masuya D, Kobayashi S, Kinoshita M, Yokomise H: Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Brit J Cancer 88: 1727-1733, 2003
23. Yoo J, Lee SH, Lym KI, Park SY, Yang SH, Yoo CY, Jung JH, Kang SJ, Kang CS: Immunohistochemical expression of DCUN1D1 in non-small cell lung carcinoma: its relation to brain metastasis. Cancer Res Treat 44: 57-62, 2012
24. Ricketts CJ, Linehan WM: Intratumoral heterogeneity in kidney cancer. Nat Genet 46: 214-215, 2014
25. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P: Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14: 1938-1946, 2008
26. Nakamura T, Kuwai T, Kitadai Y, Sasaki T, Fan D, Coombes KR, Kim SJ, Fidler IJ: Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res 67: 7597-7604, 2007
27. Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22, 2010
28. Yoshimasu T, Sakurai T, Oura S, Hirai I, Tanino H, Kokawa Y, Naito Y, Okamura Y, Ota I, Tani N, Matsuura N: Increased expression of integrin α3β1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci 95: 142-148, 2004
29. Wilhelm I, Molnár J, Fazakas C, Haskó J, Krizbai IA: Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci 14: 1383-1411, 2013
30. Sipos E, Chen L, Andras IE, Wrobel J, Zhang B, Pu H, Park M, Eum SY, Toborek M: Proinflammatory adhesion molecules facilitate polychlorinated biphenyl-mediated enhancement of brain metastasis formation. Toxicol Sci 126: 362-371, 2012
31. Shabani HK, Kitange G, Tsunoda K, Anda T, Tokunaga Y, Shibata S, Kaminogo M, Hayashi T, Ayabe H, Iseki M: Immunohistochemical expression of E-cadherin in metastatic brain tumors. Brain Tumor Pathol 20: 7-12, 2003
32. Yoo JY, Yang SH, Lee JE, Cho DG, Kim HK, Kim SH, Kim IS, Hong JT, Sung JH, Son BC, Lee SW: E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model. J Neurooncol 109: 219-227, 2012
33. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ: Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 60: 4959-4967, 2000
34. Jubb AM, Cesario A, Ferguson M, Congedo MT, Gatter KC, Lococo F, Mule A, Pezzella F: Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer 104: 1877-1881, 2011
35. Li B, Wang C, Zhang Y, Zhao XY, Huang B, Wu PF, Li Q, Li H, Liu YS, Cao LY, DaiWM, Fang WG, Shang DS, Cao L, Zhao WD, Chen YH: Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene 32: 2952-2962, 2013
36. Keeley EC, Mehrad B, Strieter RM: CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 106: 91-111, 2010
37. Fokas E, Steinbach JP, Rödel C: Biology of brain metastases and novel targeted therapies: Time to translate the research. Biochim Biophys Acta 1835: 61-75, 2013
38. Belperio JA, Phillips RJ, Burdick MD, Lutz M, Keane M, Strieter R: The SDF-1/CXCL12/ CXCR4 biological axis in non-small cell lung cancer metastases. Chest 125: 156S, 2004
39. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24: 4462-4471, 2005
40. Salmaggi A, Maderna E, Calatozzolo C, Gaviani P, Canazza A, Milanesi I, Silvani A, DiMeco F, Carbone A, Pollo B: CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther 8: 1608-1614, 2009
41. Paratore S, Banna GL, D’Arrigo M, Saita S, Iemmolo R, Lucenti L, Bellia D, Lipari H, Buscarino C, Cunsolo R, Cavallaro S: CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases. Cancer Biomark 10: 79-89, 2011
42. Feng S, Cen J, Huang Y, Shen H, Yao L, Wang Y, Chen Z: Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS One 6: e20599, 2011
43. Hu L, Zhang J, Zhu H, Min J, Feng Y, Zhang H: Biological characteristics of a specific brain metastatic cell line derived from human lung adenocarcinoma. Med Oncol 27: 708-714, 2010
44. Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H, Matsuura N: Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res 64: 4190-4196, 2004
45. Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J: Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 119: 1491-1494, 2006
46. Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, Yang CH, Lee YC, Yang PC, Shih JY: Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 4: 696-702, 2009
47. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 24: 8195-8203, 2004
48. Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 5: 430-439, 2007
49. Li Z, Guo H: The retrospective analysis of the frequency of EGFR mutations and efficacy of gefitinib in NSCLC patients with brain metastases. J Clin Oncol 29: e18065, 2011
50. Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV: EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 11: 1193-1199, 2010
51. Sekine A, Kato T, Hagiwara E, Shinohara T, Komagata T, Iwasawa T, Satoh H, Tamura K, Kasamatsu T, Hayashihara K, Saito T, Takahashi H, Ogura T: Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 77: 64-69, 2012
52. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE: Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16: 5873-5882, 2010
53. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H: Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 448: 561-566, 2007
54. Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Wöhrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, Schoppmann SF, Zielinski CC, Streubel B, Birner P: ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 80: 278-283, 2013
55. Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, Jatoi A, Deschamps C, Marks R, Fortner C, Stoddard S, Nichols F, Molina J, Aubry MC, Tang H, Yi ES: Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 7: 90-97, 2012
56. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR: Oncogene status predicts patterns of metastatic spread in treatment-naïve non-small cell lung cancer. Cancer 118: 4502-4511, 2012
57. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massagué J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138: 51-62, 2009
58. Xu HT, Wei Q, Liu Y, Yang LH, Dai SD, Han Y, Yu JH, Liu N, Wang EH: Overexpression of axin downregulates TCF-4 and inhibits the development of lung cancer. Ann Surg Oncol 14: 3251-3259, 2007
59. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM: A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 14: 5565-5570, 2008
60. Wojciak-Stothard B, Ridley AJ: Rho GTPase and the regulation of endothelial permeability. Vascul Pharmacol 39: 187-199, 2003
61. Li B, Zhao WD, Tan ZM, Fang WG, Zhu L, Chen YH: Involvement of Rho/ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett 580: 4252-4260, 2006
62. Navab R, Liu J, Seiden-Long I, Shih W, Li M, Bandarchi B, Chen Y, Lau D, Zu YF, Cescon D, Zhu CQ, Organ S, Ibrahimov E, Ohanessian D, Tsao MS: Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11: 1292-1300, 2009
63. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan B, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M: Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177: 415-423, 2010
64. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C, Lollini PL: Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-; Il2rg-/-mice and treatment with PI3K inhibitor. PLoS One 7: e39626, 2012
65. Bagnato A, Rosanò L: The endothelin axis in cancer. Int J Biochem Cell Biol 40: 1443-1451, 2008
66. Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O’Connor-McCourt MD, Kerbel RS: Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res 72: 4909-4919, 2012
67. Hanibuchi M, Kim SJ, Otsuka K, Mitsuhashi A, Goto H, Nishioka Y, Fidler IJ: Therapeutic efficacy of endothelin receptor blockade on experimental brain metastases of human non-small cell lung cancer. 18th Congress of the Asian Pacific Society of Respirology, 2013
68. Chen LT, Xu SD, Xu H, Zhang JF, Ning JF, Wang SF: MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration: invasion and tumor angiogenesis. Med Oncol 29: 1673-1680, 2012
69. Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, Ryken T, Gotway MB, Kim S, Weiss GJ: MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer 129: 2621-2631, 2011
70. Huang Q, Ouyang X: Predictive biochemicalmarkers for the development of brain metastases from lung cancer: Clinical evidence and future directions Cancer Epidemiol 37: 703-707, 2013
71. Li Q, Wu H, Chen B, Hu G, Huang L, Qin K, Chen Y, Yuan X, Liao Z: SNPs in the TGF-β signaling pathway are associated with increased risk of brain metastasis in patients with nonsmall-cell lung cancer. PLoS One 7: e51713, 2012
72. Zhang C, Zhang F, Tsan R, Fidler IJ: Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res 69: 828-835, 2009
73. Lee DS, Kim YS, Jung SL, Lee KY, Kang JH, Park S, Kim YK, Yoo IeR, Choi BO, Jang HS, Yoon SC: The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer. Tumour Biol 33: 1065-1073, 2012
74. Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E, De la Garza J: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer 9: 119, 2009
75. Yonemori K, Sumi M, Fujimoto N, Ito Y, Imai A, Kagami Y, Ikeda H: Pro-gastrin-releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation. Cancer 104: 811-816, 2005
76. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Aumayr B, Vogelbaum MA, Barnett GH, Janigro D: Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer 97: 2806-2813, 2003
77. Marchi N, Mazzone P, Fazio V, Mekhail T, Masaryk T, Janigro D: ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients. Cancer 112: 1313-1324, 2008
78. Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, Maya M, He J, Kim SW, Weihua Z, Balasubramanian K, Fan D, Mills GB, Hung MC, Fidler IJ: Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 13: 286-298, 2011
79. Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, Bar-Eli M, Aldape KD, Fidler IJ: Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12: 748-754, 2010
80. Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S, Teramoto N, Iguchi H, Noda M: Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis 28: 13-25, 2011
81. Sierra A, Price JE, Garcia-Ramirez M, Mendez O, Lopez L, Fabra A: Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab Invest 77: 357-368, 1997
82. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F: Real-time imaging reveals the single steps of brainmetastasis formation. Nat Med 16: 116-122, 2010
83. Carden CP, Larkin JM, Rosenthal MA: What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 10: 624-630, 2008
84. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP: Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16: 269-278, 2010
85. De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB: Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 100: 443-447, 2010
86. Jamal-Hanjani M, Spicer J: Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptormutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 18: 938-944, 2012
87. Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z: Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain, Lung Cancer 57: 359-364, 2007
88. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, Lee JS: Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65: 351-354, 2009
89. Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N: Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 67: 1465-1469, 2011
90. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28: 3965-3972, 2010
91. Gandhi L, Jänne PA: Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 18: 3737-3742, 2012
92. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, Wilner KD: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29: e443-e445, 2011
93. Falk AT, Poudenx M, Otto J, Ghalloussi H, Barriere J: Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report. Lung Cancer 78: 282-284, 2012